Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) hit a new 52-week low on Monday . The company traded as low as $186.61 and last traded at $186.61, with a volume of 26 shares trading hands. The stock had previously closed at $187.73.
Genmab A/S Stock Performance
The stock has a market capitalization of $12.67 billion, a PE ratio of 18.45 and a beta of 1.04. The firm’s 50 day moving average is $207.03 and its two-hundred day moving average is $230.86.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
- Five stocks we like better than Genmab A/S
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Inflation Persists, But So Do Stock Opportunities: Rally On
- What is a Bond Market Holiday? How to Invest and Trade
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
